Windtree Therapeutics Inc. (WINT)
OTC PINK OTC PINK Primary Summary
Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?
Windtree Therapeutics (NASDAQ: WINT ) stock is rocketing higher on Friday after the biotechnology company provided an update on its clinical trial of istaroxime. Windtree Therapeutics notes that it is expecting its Phase 2 Phase 2 SEISMiC Extension Study to complete enrollment within the company weeks.
Windtree Therapeutics Inc. (WINT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Windtree Therapeutics Inc. ever had a stock split?
Windtree Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jed A. Latkin CEO | OTC PINK Exchange | 97382D600 CUSIP |
| US Country | 14 Employees | - Last Dividend | 21 Feb 2025 Last Split | 8 Aug 1995 IPO Date |
Overview
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapeutics for the treatment of acute cardiovascular diseases. The company embarked on its journey in the biopharmaceutical field in 1992 and underwent a significant rebranding from Discovery Laboratories, Inc. to Windtree Therapeutics, Inc. in April 2016, marking a new era of its commitment to addressing unmet medical needs. With its headquarters located in Warrington, Pennsylvania, Windtree Therapeutics continues to push the boundaries of medical science through extensive research and development collaborations. Among its notable partnerships are those with Chang Gung University, Universita degli Studi di Milano-Bicocca, Laboratorios del Dr. Esteve, S.A., and Battelle Memorial Institute, each contributing to the advancement of Windtree’s extensive portfolio in cardiovascular and respiratory therapies.
Products and Services
- Istaroxime
- AEROSURF
- Surfaxin
- Rostafuroxin
- SERCA2a Activator (Oral and Intravenous)
Currently in Phase 2b clinical trial for acute decompensated heart failure and Phase 2a for early cardiogenic shock, istaroxime is a leading development for Windtree Therapeutics. It showcases the company's focus on acute cardiovascular conditions by aiming to improve systolic and diastolic heart function.
As an aerosolized KL4 surfactant, AEROSURF is in Phase 2b clinical trial targeting the treatment of respiratory distress syndrome in premature infants. This innovative therapy represents Windtree’s ambition in addressing critical needs in neonatal care.
This lyophilized KL4 surfactant is undergoing Phase 2a clinical trials for treating lung injury caused by COVID-19. Surfaxin exemplifies Windtree’s responsive approach to global health crises by adapting its technology to meet emerging health challenges.
Windtree is advancing Rostafuroxin into Phase 2b clinical trials, targeting genetically associated hypertension. This drug is part of Windtree’s efforts to tackle cardiovascular diseases with a genetic foundation, thereby personalizing medical care.
Still in the preclinical trial phase, this therapy is being developed for both chronic and acute heart failure. The SERCA2a activator represents Windtree's ongoing commitment to pioneering heart failure treatments, aiming to address a broad spectrum of the disease’s manifestations.
